重组人血管内皮抑制素联合同步放化疗治疗鼻咽癌的疗效观察

发布时间：2018-03-26 18:49

  本文选题：鼻咽癌　切入点：重组人血管内皮抑制素　出处：《中国现代医学杂志》2017年03期

【摘要】：目的分析重组人血管内皮抑制素联合同步放化疗对鼻咽癌患者预后和肿瘤恶性程度的影响。方法选取2012年11月-2015年1月在该院接受治疗的78例鼻咽癌患者作为研究对象,根据治疗方式分为接受重组人血管内皮抑制素联合同步放化疗的观察组36例,接受单纯同步放化疗的对照组42例。对比两组患者治疗后鼻咽癌预后相关因子蛋白表达量、血清生长因子水平、血清病情相关因子水平差异。结果观察组患者治疗后鼻咽癌标本中乙酰肝素酶、蛋白激酶CK2β、缺氧诱导因子-1α、潜伏膜蛋白蛋白表达量均低于对照组(P0.05);观察组患者治疗后血清转化生长因子β1、血小板源性生长因子-β、表皮生长因子、表皮生长因子受体、血管内皮生长因子值均低于对照组(P0.05);观察组患者治疗后血清巨噬细胞炎性蛋白-3α、α-羟基丁酸脱氢酶、细胞角蛋白19片段、胸苷激酶-1、Ⅲ型前胶原、层粘连蛋白值均低于对照组(P0.05)。结论鼻咽癌患者接受重组人血管内皮抑制素联合同步放化疗,可以降低肿瘤恶性程度并优化治疗预后,具有积极的临床意义。
[Abstract]:Objective to analyze the effects of recombinant human vascular endothelial inhibin combined with concurrent radiotherapy and chemotherapy on the prognosis and malignancy of nasopharyngeal carcinoma (NPC). Methods 78 patients with nasopharyngeal carcinoma who were treated in our hospital from November 2012 to January 2015 were selected as the study subjects. According to the treatment methods, 36 patients were treated with recombinant human vascular endothelin combined with concurrent radiotherapy and chemotherapy, and 42 patients were treated with single concurrent radiotherapy and chemotherapy. The expression levels of prognostic factors related to the prognosis of nasopharyngeal carcinoma were compared between the two groups. Results heparinase was found in patients with nasopharyngeal carcinoma after treatment. The expression of protein kinase CK2 尾, hypoxia inducible factor -1 伪 and latent membrane protein was lower than that of control group (P 0.05), and the levels of transforming growth factor 尾 1, platelet-derived growth factor- 尾, epidermal growth factor and epidermal growth factor receptor were significantly lower in the observation group after treatment. Serum macrophage inflammatory protein -3 伪, 伪 -hydroxybutyrate dehydrogenase, cytokeratin 19 fragment, thymidine kinase -1, type 鈪，

本文编号：1669133